alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 701.10 Principal display panel. The term *principal display panel* as it applies to cosmetics in package form and as used in this part, means the part of a label that is most likely to be displayed, presented, shown, or examined under customary conditions of display for retail sale. The principal display panel shall be large enough to accommodate all the mandatory label information required to be placed thereon by this part with clarity and conspicuousness and without obscuring designs, vignettes, or crowding. Where packages bear alternate principal display panels, information required to be placed on the principal display panel shall be duplicated on each principal display panel. For the purpose of obtaining uniform type size in declaring the quantity of contents of all packages of substantially the same size, the term “area of the principal display panel” means the area of the side or surface that bears the principal display panel, which area shall be: ( a ) In the case of a rectangular package where one entire side properly can be considered to be the principal display panel side, the product of the height times the width of that side;
( b ) In the case of a cylindrical or nearly cylindrical container, 40 percent of the product of the height of the container times the circumference; and
( c ) In the case of any other shape of container, 40 percent of the total surface of the container: *Provided, however,* That where such container presents an obvious “principal display panel” such as the top of a triangular or circular package, the area shall consist of the entire top surface.
In determining the area of the principal display panel, exclude tops, bottoms, flanges at the tops and bottoms of cans, and shoulders and necks of bottles or jars. In the case of cylindrical or nearly cylindrical containers, information required by this part to appear on the principal display panel shall appear within that 40 percent of the circumference which is most likely to be displayed, presented, shown, or examined under customary conditions of display for retail sale.
(logo)****CURCIO

+COHEN

 

 

**Report of IndependentRegistered Public Accounting Firm**

 

Managing Member

Park Bridge Lender ServicesLLC

New York, NY

 

 

We have examinedmanagement’s assertion, included in the accompanying Management’s Reporton Assessment of 2016 Compliance by Park Bridge Lender Services LLC withRegulation AB Servicing Criteria (“Management’s Report”),that Park Bridge Lender Services LLC (the “Company”) complied withthe servicing criteria set forth in Item 1122(d) of the U.S. Securities andExchange Commission’s Regulation AB as of and for the year ended December31, 2016, excluding those criteria noted as not applicable (N/A) within ExhibitB to Management’s Report. The transactions covered by this report areonly those transactions processed by the Company in its capacity as trustadvisor or operating advisor for the asset backed securities transactions (the“Platform”) identified in Management’s Report. ReferenceExhibit A to Management’s Report for the transactions covered by thisexamination. Management is responsible for the Company’s compliance withthe applicable servicing criteria. Our responsibility is to express an opinionon management’s assertion based on our examination.

 

Our examination was conductedin accordance with attestation standards of the Public Company AccountingOversight Board (United States) and, accordingly, included examining, on a testbasis, evidence about the Company’s compliance with the applicableservicing criteria and performing such other procedures as we considerednecessary in the circumstances. Our examination included testing of a selectedsample of the servicing activities related to the Platform, determining whetherthe Company performed those selected activities in compliance with theapplicable servicing criteria during the specified period. Our procedures werelimited to the selected transactions and servicing activities performed by theCompany during the period covered by this report. Our examination was notdesigned to detect material noncompliance arising from errors that may haveoccurred prior to or subsequent to our tests, that may have affected theCompany’s servicing activities during the period covered by this report.We believe that our examination provides a reasonable basis for our opinion.Our examination does not provide a legal determination on the Company’scompliance with the applicable servicing criteria.

 

In our opinion,management’s assertion that the Company complied with the aforementionedapplicable servicing criteria identified in Exhibit B to Management’sReport with respect to the transactions identified in Exhibit A toManagement’s Report as of and for the year ended December 31, 2016, forthe Platform, is fairly stated in all material aspects.

 

 

/s/ Curcio & Cohen,CPA’s, P.C.

 

 

New York, NY

February 2, 2017

 

 

CERTIFIED PUBLIC ACCOUNTANTSPC 7 PENN PLAZA, SUITE 1500 NEW YORK NY 10001

TEL: 212 557-9800  FAX:212 557 9819   WEBSITE: WWW.CWCCPAFIRM.COM
#### § 82.1205 D&C Green No. 5.

The color additive D&C Green No. 5 shall conform in identity and specifications to the requirements of § 74.1205(a)(1) and (b)(2) of this chapter.

[47 FR 24285, June 4, 1982]
§ 582.5530 Niacin. ( a ) *Product.* Niacin.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
Proposed Rule: Mandatory Reporting of Oil and Natural Gas and Geologic Sequestration 

Meeting Documentation Interagency Meeting – Overview of Proposal, January 7, 2010 

Date Staff Contact Information 

(Name, email, phone #) 

Name of 

Organization 

(Attach list of 

all attendees 

names and 

emails if 

possible) 

Summary of Discussion (e.g., applicability, reporting 

requirements, etc.)

Written Comments 

Provided? 

Did they also 

submit to Docket? 

Date sent to EPACCD 

1/7 Suzie Kocchi, 

Kocchi.suzanne@epa.gov

202-343-9387 

Agencies 

attending: 

EPA 

OMB 

NASA 

DOD 

DOE 

BLM 

Commerce 

MMS 

CEQ 

A conference call was held to provide the 

interagency group and overview of the 2 proposed 

GHG mandatory reporting rules: 1) oil and 

natural gas systems and 2) geologic sequestration 

 

N/A N/A
§ 820.100 Corrective and preventive action. ( a ) Each manufacturer shall establish and maintain procedures for implementing corrective and preventive action. The procedures shall include requirements for: ( 1 ) Analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems. Appropriate statistical methodology shall be employed where necessary to detect recurring quality problems;
( 2 ) Investigating the cause of nonconformities relating to product, processes, and the quality system;
( 3 ) Identifying the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems;
( 4 ) Verifying or validating the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device;
( 5 ) Implementing and recording changes in methods and procedures needed to correct and prevent identified quality problems;
( 6 ) Ensuring that information related to quality problems or nonconforming product is disseminated to those directly responsible for assuring the quality of such product or the prevention of such problems; and
( 7 ) Submitting relevant information on identified quality problems, as well as corrective and preventive actions, for management review.
( b ) All activities required under this section, and their results, shall be documented.
§ 516.2980 Verdinexor. ( a ) *Specifications.* Each tablet contains 2.5, 10, or 50 milligrams (mg) verdinexor.
( b ) *Sponsor.* See No. 086121 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Administer verdinexor tablets orally at an initial dose of 1.25 mg per kilogram (mg/kg) of body weight twice per week with at least 72 hours between doses. If tolerated after 2 weeks, increase the dose to 1.5 mg/kg twice per week with at least 72 hours between doses.
( 2 ) *Indications for use.* For the treatment of lymphoma in dogs.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal law to use this product other than as directed in the labeling.
[86 FR 57996, Oct. 20, 2021]
<PAGE>

                                                                    EXHIBIT 99.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Evergreen Solar, Inc. (the "Company") on
Form 10-K for the year ended December 31, 2002 as filed with the Securities and
Exchange Commission on the date hereof (the "Report"), I, Richard G. Chleboski,
Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
that to my knowledge:


(1)  The Report fully complies with the requirements of section 13(a) or 15(d)
of the Securities Exchange Act of 1934; and

(2)  The information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the Company.

/s/ Richard G. Chleboski
-------------------------------

Richard G. Chleboski
Chief Financial Officer
March 27, 2003


A signed original of this written statement required by Section 906 has been
provided to Evergreen Solar, Inc. and will be retained by Evergreen Solar, Inc.
and furnished to the Securities and Exchange Commission or its staff upon
request.
<PAGE>

                                                                  Exhibit 10.165

         LIST OF OMITTED SCHEDULES/EXHIBITS TO ASSET PURCHASE AGREEMENT

SCHEDULES
---------

Schedule A                          Products
Schedule 1.01(a)(i)                 Inventory
Schedule 1.01(a)(ii)                Machinery and Equipment
Schedule 1.01(a)(iii)               Bt Strains, SOPs and Technology
Schedule 1.01(a)(v)                 Product Registrations and Permits
Schedule 1.01(a)(vii)               Assumed Contracts
Schedule 1.01(a)(xi)                Other Materials
Schedule 1.05                       Purchase Price Allocation
Schedule 3.01                       Organization, Standing and Power
Schedule 3.03                       Consents and Filings - Sellers
Schedule 3.04                       Financial Statements
Schedule 3.05                       Absence of Certain Changes or Events
Schedule 3.06                       Taxes
Schedule 3.07                       Workers' and Users' Injuries
Schedule 3.08                       Litigation
Schedule 3.09                       Compliance with Applicable Laws
Schedule 3.10                       Environmental Matters
Schedule 3.11(a)(i)                 Owned Patents
Schedule 3.11(a)(ii)                Licensed Patents
Schedule 3.11(a)(iii)               Trademarks
Schedule 3.11(a)(iv)                Other Intellectual Property
Schedule 3.11(c)                    Agreements Affecting Intellectual Property
Schedule 3.11(d)(iv)                Claims
Schedule 3.11(d)(vi)                Alleged Infringement
Schedule 3.12                       Contracts
Schedule 3.12(k)                    Terminated Contracts
Schedule 3.13                       Permits and Product Registrations
Schedule 3.14                       Suppliers
Schedule 3.15                       Distributors and Customers
Schedule 3.16                       Manufacturers
Schedule 3.19                       Transactions with Affiliates
Schedule 3.20                       EPA Statements, Citations or Decisions
Schedule 3.21                       Inventory
Schedule 4.03                       Consent and Filings - Buyer
Schedule 5.01                       Conduct of Business
Schedule 10.11                      Sellers' Knowledge

EXHIBITS
--------

Exhibit A     Instrument of Assignment and Assumption
Exhibit B     Opinion of Sellers' Counsel
Exhibit C     Reilly Non-competition Agreement
Exhibit D     Opinion of Buyer's Counsel
Exhibit E     Bill of Sale
Exhibit F     Intellectual Property Collective Assignment
Exhibit G     Mycogen Letter
Exhibit H     Pre-Closing Business Arrangement Agreement
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > H.R. 28; the Federal Reserve Accountability Act of 1993

              																	United States. Congress. House. Committee on Banking, Finance, and Urban Affairs, 1977-1995					 and 	One Hundred Third Congress, 1993-1995. 						*H.R. 28; the Federal Reserve Accountability Act of 1993 : Hearing Before the Committee on Banking, Finance, and Urban Affairs, House of Representatives, One Hundred Third Congress, First Session, October 19, 1993*,												Washington: 								U.S. Government Printing Office, 										October 19, 1993,									https://fraser.stlouisfed.org/title/1155,			accessed on September 16, 2024.						    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
§ 520.62 Aminopentamide. ( a ) *Specifications.* Each tablet contains 0.2 milligram (mg) aminopentamide hydrogen sulphate.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs and cats* — ( 1 ) *Amount.* Administer orally every 8 to 12 hours as follows: For animals weighing up to 10 pounds (lbs): 0.1 mg; for animals weighing 11 to 20 lbs: 0.2 mg; for animals weighing 21 to 50 lbs: 0.3 mg; for animals weighing 51 to 100 lbs: 0.4 mg; for animal weighing over 100 lbs: 0.5 mg. Dosage may be gradually increased up to a maximum of five times the suggested dosage. Oral administration of tablets may be preceded by subcutaneous or intramuscular use of the injectable form of the drug.
( 2 ) *Indications for use.* For the treatment of vomiting and/or diarrhea, nausea, acute abdominal visceral spasm, pylorospasm, or hypertrophic gastritis.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 28816, May 20, 2014]
§ 814.2 Purpose. The purpose of this part is to establish an efficient and thorough device review process— ( a ) To facilitate the approval of PMA's for devices that have been shown to be safe and effective and that otherwise meet the statutory criteria for approval; and
( b ) To ensure the disapproval of PMA's for devices that have not been shown to be safe and effective or that do not otherwise meet the statutory criteria for approval. This part shall be construed in light of these objectives.
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                       8,847,000
<SECURITIES>                                         0
<RECEIVABLES>                                3,688,000
<ALLOWANCES>                                 (228,000)
<INVENTORY>                                          0
<CURRENT-ASSETS>                            23,574,000
<PP&E>                                     844,381,000
<DEPRECIATION>                            (14,374,000)
<TOTAL-ASSETS>                             863,512,000
<CURRENT-LIABILITIES>                       41,538,000
<BONDS>                                    246,703,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                      2,000
<COMMON>                                        30,000
<OTHER-SE>                                 570,107,000
<TOTAL-LIABILITY-AND-EQUITY>               863,512,000
<SALES>                                              0
<TOTAL-REVENUES>                            66,150,000
<CGS>                                                0
<TOTAL-COSTS>                               31,140,000
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                          11,022,000
<INCOME-PRETAX>                             23,988,000
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                              (808,000)
<CHANGES>                                            0
<NET-INCOME>                                22,688,000
<EPS-PRIMARY>                                     1.12
<EPS-DILUTED>                                     1.09


</TABLE>
# C_2014159EN.01001302.xml

| 26.5.2014 | EN | Official Journal of the European Union | C 159/13 |
| --- | --- | --- | --- |

26.5.2014

EN

Official Journal of the European Union

C 159/13

---

Request for a preliminary ruling from the Amtsgericht Rüsselsheim (Germany) lodged on 12 March 2014 — Henricus Cornelis Maria Niessen and Others v Condor Flugdienst GmbH

(Case C-119/14)

2014/C 159/18

Language of the case: German

Referring court

Referring court

Amtsgericht Rüsselsheim

Parties to the main proceedings

Parties to the main proceedings

Applicants: Henricus Cornelis Maria Niessen, Angelique Francisca Niessen-Steeghs, Melissa Alexandra Johanna Niessen, Kenneth Gerardus Henricus Niessen

Applicants:

Defendant: Condor Flugdienst GmbH

Defendant:

Questions referred

Questions referred

| 1. | Are adverse actions by third parties acting on their own responsibility and to whom certain tasks that constitute part of the operation of an air carrier have been entrusted, to be deemed to be extraordinary circumstances within the meaning of Article 5(3) of Regulation No 261/2004? (1) |
| --- | --- |

1.

Are adverse actions by third parties acting on their own responsibility and to whom certain tasks that constitute part of the operation of an air carrier have been entrusted, to be deemed to be extraordinary circumstances within the meaning of Article 5(3) of Regulation No 261/2004? (1)

1

| 2. | If the answer to Question 1 is in the affirmative, does the assessment of the situation depend on who (airline, airport operator etc.) entrusted the task(s) to the third party? |
| --- | --- |

2.

If the answer to Question 1 is in the affirmative, does the assessment of the situation depend on who (airline, airport operator etc.) entrusted the task(s) to the third party?

---

(1)  Regulation (EC) No 261/2004 of the European Parliament and of the Council of 11 February 2004 establishing common rules on compensation and assistance to passengers in the event of denied boarding and of cancellation or long delay of flights, and repealing Regulation (EEC) No 295/91 (OJ 2004 L 46, p. 1).

1

---
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1200 Corticosterone test system. ( a ) *Identification.* A corticosterone test system is a device intended to measure corticosterone (a steroid secreted by the adrenal gland) levels in plasma. Measurements of corticosterone are used in the diagnosis and treatment of adrenal disorders such as adrenal cortex disorders and blocks in cortisol synthesis.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2305, Jan. 14, 2000]
Exhibit 21 - Subsidiaries of the Company


                 Subsidiaries of the Company


                 Subsidiary          Jurisdiction of Incorporation

               iConcepts, Inc.                     Virginia
                BOTWEB, Inc.                       Virginia
# C_2019008EN.01000101.xml

| 9.1.2019 | EN | Official Journal of the European Union | C 8/1 |
| --- | --- | --- | --- |

9.1.2019

EN

Official Journal of the European Union

C 8/1

---

DECISION

(2019/C 8/01)

THE SECRETARY-GENERAL OF THE EUROPEAN PARLIAMENT,

| — | HAVING REGARD TO Council Regulation (EEC, Euratom, ECSC) No 259/68 (1), as amended in particular by Regulation (EU, Euratom) No 1023/2013 of the European Parliament and of the Council of 22 October 2013 (2) and, in particular, Article 30 of those Staff Regulations, |
| --- | --- |

—

HAVING REGARD TO Council Regulation (EEC, Euratom, ECSC) No 259/68 (1), as amended in particular by Regulation (EU, Euratom) No 1023/2013 of the European Parliament and of the Council of 22 October 2013 (2) and, in particular, Article 30 of those Staff Regulations,

| — | HAVING REGARD TO the Bureau Decision of 13 January 2014 on the delegation of the powers of the appointing authority and of the authority empowered to conclude contracts of employment (AECE), |
| --- | --- |

—

HAVING REGARD TO the Bureau Decision of 13 January 2014 on the delegation of the powers of the appointing authority and of the authority empowered to conclude contracts of employment (AECE),

| — | HAVING REGARD TO the expiry, on 31 December 2018, of the following European Parliament reserve lists:
  AD/1/13, AST/4/11, AST/1/13, PE/168/S, PE/171/S, PE/185/S, PE/186/S, |
| --- | --- |

—

HAVING REGARD TO the expiry, on 31 December 2018, of the following European Parliament reserve lists:

AD/1/13, AST/4/11, AST/1/13, PE/168/S, PE/171/S, PE/185/S, PE/186/S,

| — | HAVING REGARD TO the opinion of the Joint Committee issued at its meeting of 24 October 2018, |
| --- | --- |

—

HAVING REGARD TO the opinion of the Joint Committee issued at its meeting of 24 October 2018,

HAS DECIDED

Sole Article

The period of validity of the following reserve lists:

AD/1/13, AST/4/11, AST/1/13, PE/168/S, PE/171/S, PE/185/S, PE/186/S,

shall be extended until 31 December 2019.

Luxembourg, 30 November 2018.

Klaus WELLE

Secretary-General

---

(1)  OJ L 56, 4.3.1968, p. 1.

1

(2)  OJ L 287, 29.10.2013, p. 15.

2

---